Angeline Ginzac (Angeline Ginzac Couvé)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Venues

Breast cancer research and treatment

BMC cancer

F1000Research

Cancer medicine

Centre Jean PERRIN

Université Clermont Auvergne (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centre Jean PERRIN Apr 01 2019

France

Project manager :: Clinical research

Centre Jean Perrin - Mar 31 2019

France

PhD student :: Clinical Research

Centre Jean Perrin - Mar 31 2019

France

Clinical Research Associate :: Clinical Research

Education History

Université Clermont Auvergne - Apr 03 2019

France

PHD :: Ecole doctorale des sciences de la vie, santé, agronomie et environnement

Université Clermont Auvergne

France

MSC

Université Blaise Pascal

France

BSC

Publications

Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Veronique D'Hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast cancer research and treatment 205 (2) (2024)
Angeline Ginzac, Marie-Céleste Ferreira, Anne Cayre, Clément Bouvet, Julian Biau, Ioana Molnar, Nicolas Saroul, Nathalie Pham-Dang, Xavier Durando, Maureen Bernadach
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): a study protocol for a prospective, multicentre trial. BMC cancer 23 (1) (2023)
Tressie Herrmann, Angeline Ginzac, Ioana Molnar, Sébastien Bailly, Xavier Durando, Hakim Mahammedi
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer medicine 10 (19) (2021)
Passildas Jahanmohan Judith, Jean-Christophe Eymard, Mélanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac, Emilie Thivat, Brigitte Monange, Philippe Chollet, Hakim Mahammedi
Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer. Cancer medicine 10 (7) (2021)
Angeline Ginzac, Guillaume Dupic, Lucie Brun, Ioana Molnar, Mélanie Casile, Xavier Durando, Pierre Verrelle, Jean-Jacques Lemaire, Toufic Khalil, Julian Biau
Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial. BMC cancer 21 (1) (2021)
Angeline Ginzac, Sophie Dubois, Marie-Odile Hager, Fabrice Kwiatkowski, Judith Passildas, Julian Biau, Catherine Abrial, Marie-Ange Mouret-Reynier, Emilie Thivat, Xavier Durando
Quality of life for older patients with cancer: a review of the evidence supporting melatonin use. Aging clinical and experimental research 32 (12) (2020)
Angeline Ginzac, Bertrand Barres, Marion Chanchou, Emilie Gadéa, Ioana Molnar, Charles Merlin, Bruno Coudert, Emilie Thivat, Xavier Durando
A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients. BMC cancer 20 (1) (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)
Céleste Pinard, Judith Passildas, Angeline Ginzac, Sejdi Lusho, Yannick Bidet, Ioana Molnar, Maureen Bernadach, Mathias Cavaille, Nina Radosevic-Robin, Xavier Durando
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer. F1000Research 9 (2020)

Angeline Ginzac.css-eqlu8i{font-size:small;padding-left:4px;} (Angeline Ginzac Couvé)

Publication Activity (10 Years)

Top Topics

Top Venues

Angeline Ginzac (Angeline Ginzac Couvé)